Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease

[1]  J. Roberts,et al.  Genetic susceptibility testing for neurodegenerative diseases: Ethical and practice issues , 2013, Progress in Neurobiology.

[2]  R. Blendon,et al.  Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease , 2013, Alzheimer's Research & Therapy.

[3]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[4]  M. Baumgart,et al.  The Impact of Experience with a Family Member with Alzheimer's Disease on Views about the Disease across Five Countries , 2012, International journal of Alzheimer's disease.

[5]  Regina Berretta,et al.  Multivariate Protein Signatures of Pre-Clinical Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Plasma Proteome Dataset , 2012, PloS one.

[6]  Joshua T. Cohen,et al.  Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. , 2012, Health economics.

[7]  R. Green,et al.  Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. , 2011, Genetic testing and molecular biomarkers.

[8]  D McDaid,et al.  The economic impact of dementia in Europe in 2008—cost estimates from the Eurocode project , 2011, International journal of geriatric psychiatry.

[9]  Susan E. Hahn,et al.  Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors: Erratum , 2011, Genetics in Medicine.

[10]  R. Green,et al.  Differences Between African American and White Research Volunteers in Their Attitudes, Beliefs and Knowledge Regarding Genetic Testing for Alzheimer’s Disease , 2011, Journal of Genetic Counseling.

[11]  Richard Mayeux,et al.  Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors , 2011, Genetics in Medicine.

[12]  R. Green,et al.  Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk , 2011, Genetics in Medicine.

[13]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[14]  Anne Corbett,et al.  Alzheimer's disease , 2011, The Lancet.

[15]  C. Ballard,et al.  Dementia: challenges and promising developments , 2011, The Lancet Neurology.

[16]  Ronald C. Petersen,et al.  Revision of the criteria for Alzheimer's disease: A symposium , 2011, Alzheimer's & Dementia.

[17]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[18]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .

[19]  Perry W. Payne,et al.  Regional differences in awareness and attitudes regarding genetic testing for disease risk and ancestry , 2010, Human Genetics.

[20]  Sudha Seshadri,et al.  Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.

[21]  K. Blennow,et al.  CSF Biomarkers , 2009, Annals of the New York Academy of Sciences.

[22]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[23]  J. Roberts,et al.  Black and White Adult Family Members' Attitudes Toward a Dementia Diagnosis , 2009, Journal of the American Geriatrics Society.

[24]  E. Oster,et al.  Genetic Adverse Selection: Evidence from Long-Term Care Insurance and Huntington Disease , 2009 .

[25]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[26]  C. Tufanaru,et al.  Health Belief Model , 2009 .

[27]  T. Golde.  Alzheimer's Research & Therapy , 2009 .

[28]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[29]  E. Oster,et al.  Fear of health insurance loss among individuals at risk for Huntington disease , 2008, American journal of medical genetics. Part A.

[30]  Klasien Horstman,et al.  European practices of genetic information and insurance: lessons for the Genetic Information Nondiscrimination Act. , 2008, JAMA.

[31]  C. Connell,et al.  Public Opinion About Alzheimer Disease Among Blacks, Hispanics, and Whites: Results From a National Survey , 2007, Alzheimer disease and associated disorders.

[32]  Robert West,et al.  Cambridge Handbook of Psychology, Health and Medicine: List of contributors , 2007 .

[33]  R. Green,et al.  Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. , 2006, Patient education and counseling.

[34]  S. Domchek,et al.  Low rates of acceptance of BRCA1 and BRCA2 test results among African American women at increased risk for hereditary breast-ovarian cancer , 2006, Genetics in Medicine.

[35]  O. Olopade,et al.  Confronting genetic testing disparities: knowledge is power. , 2005, JAMA.

[36]  R. Green,et al.  Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. , 2005, Health affairs.

[37]  I. Rosenstock,et al.  Some influences on public participation in a genetic screening program , 2005, Journal of Community Health.

[38]  E. Singer,et al.  Racial and ethnic variations in knowledge and attitudes about genetic testing. , 2004, Genetic testing.

[39]  R. Green,et al.  Who seeks genetic susceptibility testing for Alzheimer’s disease? Findings from a multisite, randomized clinical trial , 2004, Genetics in Medicine.

[40]  K. Armstrong,et al.  The association between race and attitudes about predictive genetic testing. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[41]  G. Halasz.  An Ethical Perspective , 2002 .

[42]  R. Deyo.  Cascade effects of medical technology. , 2002, Annual review of public health.

[43]  K S Kosik,et al.  Public attitudes about genetic testing for Alzheimer's disease. , 2001, Health affairs.

[44]  G. Evers‐Kiebooms,et al.  The psychological complexity of predictive testing for late onset neurogenetic diseases and hereditary cancers: implications for multidisciplinary counselling and for genetic education. , 2000, Social science & medicine.

[45]  P. Devilee,et al.  Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation , 2000, The Lancet.

[46]  Robertson Js,et al.  Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. , 2000 .

[47]  S. Nolen-Hoeksema,et al.  Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. , 2000, The Gerontologist.

[48]  E. Mandelkow,et al.  Tau in Alzheimer's disease. , 1998, Trends in cell biology.

[49]  R. Croyle,et al.  The new genetics: Psychological responses to genetic testing , 1998 .

[50]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[51]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[52]  J. Passchier,et al.  Psychological distress in applicants for predictive DNA testing for autosomal dominant, heritable, late onset disorders. The Rotterdam/Leiden Genetics Workgroup. , 1997, Journal of medical genetics.

[53]  A. Roses,et al.  The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. , 1997, JAMA.

[54]  B. Rimer,et al.  Genetic testing for breast cancer susceptibility: awareness and interest among women in the general population. , 1997, American journal of medical genetics.

[55]  R. Green,et al.  Early detection of Alzheimer disease: methods, markers, and misgivings. , 1997, Alzheimer disease and associated disorders.

[56]  B. Trock,et al.  BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. , 1996, JAMA.

[57]  N. Holtzman,et al.  Offering cystic fibrosis carrier screening to an HMO population: factors associated with utilization. , 1994, American journal of human genetics.

[58]  M. Morris,et al.  Reluctance to undergo predictive testing: the case of Huntington disease. , 1993, American journal of medical genetics.

[59]  K. Glanz,et al.  Health behavior and health education : theory, research, and practice , 1991 .

[60]  S. M. Miller,et al.  Monitoring and blunting: validation of a questionnaire to assess styles of information seeking under threat. , 1987, Journal of personality and social psychology.

[61]  M. Becker,et al.  The Health Belief Model: A Decade Later , 1984, Health education quarterly.

[62]  I. Rosenstock.  Why people use health services. , 1966, The Milbank Memorial Fund quarterly.